Latest news with #SaulFaust
STV News
29-04-2025
- Health
- STV News
World-first clinical trial launched in the UK for a fridge-free vaccine
A world-first clinical trial has been launched in the UK for a fridge-free vaccine, which could greatly increase access to jabs. The Stablepharma tetanus-diphtheria vaccine (SPVX02) is completely stable at room temperature and the firm behind it says up to 60 other vaccines may benefit from the advanced technology. The first-in-human trial of the vaccine is taking place at the National Institute for Health and Care Research (NIHR) Southampton clinical research facility at University Hospital Southampton. One of the biggest barriers to people getting vaccines in some parts of the world is the 'cold chain' required to keep vaccines cold from manufacture to the point they are injected. The World Health Organisation (WHO) estimates that up to half of vaccines are wasted globally every year – largely because of a lack of temperature control and the logistics needed to support an unbroken cold-chain. UK-based biotech company Stablepharma has shown it can converts existing approved vaccines to fridge-free versions that can be stored for long periods of time at room temperature. Health and Social Care Secretary, Wes Streeting, said: 'For years, vaccines have been held back by the need to be stored in a fridge – causing endless amounts of wastage and making it difficult to deliver them to remote communities. 'But thanks to this Government's vision and our investment through the National Institute for Health and Care Research, all that could be about to change. 'We are leading the charge by pushing through the world's first trial for fridge-free vaccines. 'This could be a real game changer and lifesaver globally – as it unlocks new ways for poorer nations to deliver vaccines to their patients, where they're often needed the most. 'Groundbreaking science is amongst the things that Britain does best, and this innovation reaffirms our position as a world leader in vaccine development and research, boosting growth and economic security – the cornerstone of our Plan for Change.' The clinical trial is being led by Professor Saul Faust from the University of Southampton and Stablepharma chief development officer, Dr Karen O'Hanlon. Prof Faust said: 'It is fantastic to see cutting-edge UK science reach the milestone of a first clinical trial and to be able to give the opportunity for people living on the south coast to take part. 'This research will be an important step toward exploring whether this innovation could eradicate vaccine wastage and move away from the need for the cold-chain.' The trial is expected to complete this summer, with results published by the end of the year. Stablepharma hopes the new vaccine will be in use globally by 2027. Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
BBC News
29-04-2025
- Health
- BBC News
Work to launch 'fridge-free' vaccine under way in Southampton
A vaccine that does not need to be kept in a fridge or frozen has entered its first clinical Stablepharma tetanus-diphtheria vaccine (SPVX02) is completely stable at room temperature and is ready to be trialled through a government-backed first in-human trial is being held at the National Institute for Health and Care Research's (NIHR) base at University Hospital Southampton this World Health Organization (WHO) estimates that about half of all vaccines are wasted around the world, in part because of the "cold chain" needed for them. Stablepharma, a UK-based company, has shown it can convert existing approved vaccines to fridge-free versions that can be stored at room temperate."It is fantastic to see cutting-edge UK science reach the milestone of a first clinical trial and to be able to give the opportunity for people living on the South Coast to take part," Prof Saul Faust, director of the NIHR's Southampton Clinical Research Facility, said."This research will be an important step toward exploring whether this innovation could eradicate vaccine wastage and move away from the need for the cold chain." Wes Streeting, the health and social care secretary, said the plan could be a "real game changer and lifesaver globally".Stablepharma hopes the vaccine will be in use globally by Jonathan Van-Tam, the former deputy chief medical officer for England and a member of Stablepharma's advisory board, said the vaccine could be "revolutionary for the entire vaccine industry"."Fridge-free vaccines could, in the future, play a major role in delivering the WHO's ambitions for universal health coverage," he added. You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram.
ITV News
29-04-2025
- Health
- ITV News
World-first clinical trial launched in Southampton for a fridge-free vaccine
A world-first clinical trial has been launched in the UK for a fridge-free vaccine, which could greatly increase access to jabs. The Stablepharma tetanus-diphtheria vaccine (SPVX02) is completely stable at room temperature and the firm behind it says up to 60 other vaccines may benefit from the advanced technology. The first-in-human trial of the vaccine is taking place at the National Institute for Health and Care Research (NIHR) Southampton clinical research facility at University Hospital Southampton. One of the biggest barriers to people getting vaccines in some parts of the world is the 'cold chain' required to keep vaccines cold from manufacture to the point they are injected. The World Health Organisation (WHO) estimates that up to half of vaccines are wasted globally every year – largely because of a lack of temperature control and the logistics needed to support an unbroken cold-chain. UK-based biotech company Stablepharma has shown it can convert existing approved vaccines to fridge-free versions that can be stored for long periods of time at room temperature. Health and Social Care Secretary, Wes Streeting, said: 'For years, vaccines have been held back by the need to be stored in a fridge – causing endless amounts of wastage and making it difficult to deliver them to remote communities. 'But thanks to this Government's vision and our investment through the National Institute for Health and Care Research, all that could be about to change. 'We are leading the charge by pushing through the world's first trial for fridge-free vaccines. 'This could be a real game changer and lifesaver globally – as it unlocks new ways for poorer nations to deliver vaccines to their patients, where they're often needed the most. 'Groundbreaking science is amongst the things that Britain does best, and this innovation reaffirms our position as a world leader in vaccine development and research, boosting growth and economic security – the cornerstone of our Plan for Change.' The clinical trial is being led by Professor Saul Faust from the University of Southampton and Stablepharma chief development officer, Dr Karen O'Hanlon. Prof Faust said: 'It is fantastic to see cutting-edge UK science reach the milestone of a first clinical trial and to be able to give the opportunity for people living on the south coast to take part. 'This research will be an important step toward exploring whether this innovation could eradicate vaccine wastage and move away from the need for the cold-chain.' The trial is expected to complete this summer, with results published by the end of the year. Stablepharma hopes the new vaccine will be in use globally by 2027.
Daily Mirror
29-04-2025
- Health
- Daily Mirror
World-first clinical trial launched for fridge-free vaccine that could revolutionise healthcare
The Stablepharma tetanus-diphtheria vaccine (SPVX02) does not need to be stored in a fridge and the firm behind it says up to 60 other vaccines may benefit from the technology The UK is paving the way for medical advancement with the launch of a first-of-its-kind clinical trial of a vaccine that doesn't require refrigeration. This could potentially revolutionise vaccine distribution. This groundbreaking initiative tests the tetanus-diphtheria vaccine (SPVX02) developed by Stablepharma, which stays perfectly stable at ambient temperatures. The company is optimistic about leveraging this technology to help up to 60 other vaccines avoid the fridge. Currently, the vaccine's human trial is underway at the National Institute for Health and Care Research (NIHR) Southampton clinical research facility situated in University Hospital Southampton. One of the major hurdles in immunization efforts, particularly in certain regions around the world, is maintaining the "cold chain" – the vital cool conditions from production until administration of the vaccine. According to the World Health Organisation (WHO), nearly half of the vaccines globally are discarded each year, with improper temperature control and cold-chain logistical issues largely to blame .Stablepharma, a UK-based biotech firm, has demonstrated that it can transform existing, approved vaccines into non-refrigerated versions with the potential for long-term room temperature storage. Health and Social Care Secretary Wes Streeting applauded the development: "For years, vaccines have been held back by the need to be stored in a fridge – causing endless amounts of wastage and making it difficult to deliver them to remote communities." He heralded what may be a turning point brought by this cutting-edge research: "But thanks to this Government's vision and our investment through the National Institute for Health and Care Research, all that could be about to change." 'We are leading the charge by pushing through the world's first trial for fridge-free vaccines. "This could be a real game changer and lifesaver globally – as it unlocks new ways for poorer nations to deliver vaccines to their patients, where they're often needed the most." The health secretary added: "Groundbreaking science is amongst the things that Britain does best, and this innovation reaffirms our position as a world leader in vaccine development and research, boosting growth and economic security – the cornerstone of our Plan for Change." Professor Saul Faust from the University of Southampton and Dr Karen O'Hanlon, chief development officer at Stablepharma, are guiding the pivotal clinical trial. Prof Faust said: "It is fantastic to see cutting-edge UK science reach the milestone of a first clinical trial and to be able to give the opportunity for people living on the south coast to take part. "This research will be an important step toward exploring whether this innovation could eradicate vaccine wastage and move away from the need for the cold-chain." Expectations are high that the study will wrap up by summer, with results awaiting release by year-end. With ambitious targets set by Stablepharma, the innovative vaccine could be deployed worldwide by 2027.
The Independent
29-04-2025
- Health
- The Independent
World-first trial for ‘room temperature' vaccines launched in the UK as nearly half go to waste
A world-first clinical trial for a fridge-free vaccine has been launched in the UK which could greatly increase access to jabs in the future. The firm behind a vaccine that is completely stable at room temperature – the Stablepharma tetanus-diphtheria vaccine (SPVX02) – says up to 60 other vaccines may benefit from the advanced technology it uses. The National Institute for Health and Care Research (NIHR) Southampton clinical research facility at University Hospital Southampton will house the first-in-human trial of the vaccine. The requirement to keep most vaccines in a 'cold chain' remains one of the biggest barriers to people getting accines in some part of the world. It can often prove challenging to maintain the conditions needed from manufacture to the point of injection. The World Health Organisation (WHO) estimates that up to half of vaccines are wasted globally every year – largely because of a lack of temperature control and the logistics needed to support an unbroken cold-chain. UK-based biotech company Stablepharma has shown it can converts existing approved vaccines to fridge-free versions that can be stored for long periods of time at room temperature. Health and Social Care Secretary, Wes Streeting, said: 'For years, vaccines have been held back by the need to be stored in a fridge – causing endless amounts of wastage and making it difficult to deliver them to remote communities. 'But thanks to this Government's vision and our investment through the National Institute for Health and Care Research, all that could be about to change. 'We are leading the charge by pushing through the world's first trial for fridge-free vaccines. 'This could be a real game changer and lifesaver globally – as it unlocks new ways for poorer nations to deliver vaccines to their patients, where they're often needed the most. 'Groundbreaking science is amongst the things that Britain does best, and this innovation reaffirms our position as a world leader in vaccine development and research, boosting growth and economic security – the cornerstone of our Plan for Change.' The clinical trial is being led by Professor Saul Faust from the University of Southampton and Stablepharma chief development officer, Dr Karen O'Hanlon. Prof Faust said: 'It is fantastic to see cutting-edge UK science reach the milestone of a first clinical trial and to be able to give the opportunity for people living on the south coast to take part. 'This research will be an important step toward exploring whether this innovation could eradicate vaccine wastage and move away from the need for the cold-chain.' The trial is expected to complete this summer, with results published by the end of the year. Stablepharma hopes the new vaccine will be in use globally by 2027.
